share_log

Trade Alert: President of Patient & Testing Services Of CareDx Alexander Johnson Has Sold Stock

Trade Alert: President of Patient & Testing Services Of CareDx Alexander Johnson Has Sold Stock

交易提醒:CareDx患者及檢測服務總裁亞歷山大·約翰遜出售了股票
Simply Wall St ·  08/24 20:21

Some CareDx, Inc (NASDAQ:CDNA) shareholders may be a little concerned to see that the President of Patient & Testing Services, Alexander Johnson, recently sold a substantial US$1.1m worth of stock at a price of US$33.55 per share. That's a big disposal, and it decreased their holding size by 45%, which is notable but not too bad.

一些CareDx, Inc (納斯達克:CDNA)的股東可能會稍微擔心看到患者與測試服務總裁Alexander Johnson最近以每股33.55美元的價格大量賣出價值110萬美元的股票。 這是一次大規模的剝離,使他們持股量減少了45%,這是值得注意但並不算太糟糕的。

CareDx Insider Transactions Over The Last Year

過去一年裏的CareDx內部交易

Notably, that recent sale by Alexander Johnson is the biggest insider sale of CareDx shares that we've seen in the last year. That means that an insider was selling shares at around the current price of US$31.54. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

值得注意的是,Alexander Johnson最近的這次賣出是我們在過去一年中看到的CareDx股票內部賣出中規模最大的一次。 這意味着內部人士正在以約31.54美元的當前價格出售股票。 雖然我們通常不喜歡看到內部人士銷售股票,但如果銷售發生在較低的價格上,則更令人擔憂。 我們注意到此次銷售發生在當前價格附近,因此這並不是一個重大問題,但也幾乎不能算一個好兆頭。

Insiders in CareDx didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

過去一年裏,CareDx的內部人士沒有買入任何股票。 您可以在下面看到內部人士交易(包括公司和個人)在過去的12個月中的可視化展示。 如果您單擊圖表,您可以查看所有交易,包括股票價格,個人和日期!

1724501820824
NasdaqGM:CDNA Insider Trading Volume August 24th 2024
納斯達克GM:CDNA內幕交易成交量於2024年8月24日

I will like CareDx better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

如果我看到一些大的內幕交易買入,我會更喜歡CareDx。在我們等待的時候,可以查看這個免費的被低估的小盤股列表,其中有相當多的近期內幕交易買入。

Insider Ownership Of CareDx

CareDx內部持股情況

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that CareDx insiders own 2.6% of the company, worth about US$42m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

對於普通股東來說,了解公司內部人持有多少股份是非常重要的。如果內部人員擁有大量股份,這是一個很好的跡象。據我所知,CareDx內部人持有公司的2.6%股份,價值約4200萬美元。雖然我們在其他地方看到過更高的內部持股水平,但這些持股足以表明內部人員與其他股東的利益一致。

So What Does This Data Suggest About CareDx Insiders?

那麼這些數據對於CareDx內部人來說意味着什麼呢?

Insiders haven't bought CareDx stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. Insiders own shares, but we're still pretty cautious, given the history of sales. We'd practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing CareDx. To assist with this, we've discovered 3 warning signs that you should run your eye over to get a better picture of CareDx.

過去三個月內,內部人員沒有買入CareDx股票,但有一些賣出。過去一年內沒有任何購買行爲給我們帶來安全感。儘管內部人員擁有股份,但考慮到減持的歷史,我們仍然非常謹慎。在購買之前,我們建議要謹慎一些!除了了解正在進行的內部交易,還有助於識別CareDx面臨的風險。爲此,我們發現了3個警告信號,您可以仔細查看以更好地了解CareDx。

Of course CareDx may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

當然,CareDx可能不是最好的股票買入選擇。所以您可能希望看一下這個優質公司的免費收藏。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論